LL-37

LL‑37 is the only human cathelicidin peptide and is used off‑label for its broad‑spectrum antimicrobial activity, wound‑healing support, and immune‑modulating effects. Community users typically dose around 200 µg daily, with reported amounts ranging from 25 µg up to 10 mg, and most administer it each day without a set cycle. The main caveat is that the off‑label evidence base is thin, and no FDA‑approved indication exists; side‑effect reports are limited, with occasional injection‑site irritation, occasional edema or fluid retention, and occasional nausea, while other expected reactions have not been observed.

Half-life~1 h

Data last updated

ClinicalResearchDepthClinicalResearchEfficacyClinicalResearchSideEffectsno dataAnecdotalEfficacyAnecdotalSideEffectsPrice2.01.73.03.14.0

Measured on 5 of 6 axes

Research Evidence

Evidence shape

LL-37 possesses limited human evidence, restricted primarily to diagnostic and mechanistic studies rather than therapeutic intervention. While three published studies exist, the clinical literature remains thin, with only one registered trial addressing diabetic foot ulcers and no completed trials to establish efficacy or safety. The current research landscape is dominated by preclinical and mechanistic work, leaving the peptide without the robust, large-scale human data required to support its use for specific clinical indications.

Depthhow much
1 registered trial
Breadthhow many areas
3 indications mapped
2 thin / exploratory · 1 animal-only · 1 single-trial long-tail
Qualityhow rigorous
No completed trials
1 linked publication on registered trials
Breadth and depth25 rows captured
Human
direct clinical signal
4
Animal
translational support
12
In vitro
mechanistic support
9
HighMediumLow

Anecdotal efficacy

LL-37 side effects

Clinical research side effects

Clinical safety table not projected yet.

Anecdotal side effects

Price

Full buying guide →
1
High Purity Peptides
Hong Kong
50 mg×10
$70.00
$1.4/mg
2
Uther
unknown
50 mg×10
$95.00
$1.9/mg
3
Lilipeptide
China
50 mg×10
$110.00
$2.2/mg
4
Chimera Peptides
CN
50 mg×10
$139.00
$2.78/mg
5
peptidesourcehub.com
CN
50 mg
$149.90
$3/mg
6
Saiyan Med
US
50 mg×10
$151.00
$3.02/mg

price offers can be sorted by column · 16 out-of-stock offers not shown

1-6 of 109

LL-37 dosing & protocol

How LL-37 is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.

Research trials
Published clinical-trial protocols
Typical dose
—
0
2 mg
4 mg
6 mg
8 mg
10 mg
no dose captured for this tier yet
Frequency
not reported
Route
topical

Zero completed trials have been identified for LL-37 in research trials, so dosing for this tier has not been reliably extracted.

Clinician practice
Doctor & published-protocol guidance
Typical dose
—
0
2 mg
4 mg
6 mg
8 mg
10 mg
no dose captured for this tier yet

No structured protocol details captured for this tier yet.

Anecdotal
Community-reported real-world use · n = 15
Typical dose
200 µg25 µg – 10 mg
typical
0
2 mg
4 mg
6 mg
8 mg
10 mg
distribution of 15 reported doses · darker = more
By reported cadence· tap a row to filter the chart
Frequency
mostly daily
Route
subQ

Most users (7 of 15) give LL‑37 subQ daily, typically about 200 µg (reported range 100 µg–10 mg); one user doses three times weekly at 1 mg, and another 7 report doses without a set schedule, usually 500 µg. No cycling is noted.

15 sources

Related peptides

ThymalinThymosin Alpha-1ThymulinVIP